Shield Therapeutics Appoints Richard Jones as Chief Financial Officer
Richard has more than 12 years of corporate finance and broking experience and was most recently Director and Head of Healthcare at Brewin Dolphin Investment Banking. During this time he has developed a wealth of experience in advising healthcare companies on financing transactions, including public market transactions, mergers and acquisitions. From early 2007 to October 2009, Richard was Director and Head of Healthcare at Investec Investment Banking and has also previously held various management roles within industry having originally trained as a chartered accountant at PricewaterhouseCoopers. Richard has been working closely with Shield’s management team as a non-executive Director and member of the Company’s Board since early 2010, having previously been retained as an advisor to the management team since 2008.
Carl Sterritt, Chief Executive Officer of Shield Therapeutics, commented: "We are delighted to welcome Richard to Shield’s management team at this important time in the Company’s development. Richard brings to Shield significant investment banking and strategic financial management experience, with a strong commercial focus. We look forward to him quickly becoming a pivotal member of our highly experienced team as we prepare to initiate late-stage clinical trials for ST10-021, our lead product for the treatment of iron deficiency anaemia.”
Richard Jones added: “During my time as a non-executive Director of Shield, I have been very impressed by the experienced team and excited by the commercial opportunities presented by ST10-021. I very much look forward to working more closely with them in this operational role as we continue to build upon the momentum that the Company has achieved to date.”
For more information about Shield, please contact:
Shield Therapeutics
Carl Sterritt, Chief Executive Officer
Richard Jones, Chief Financial Officer
Tel: +44 (0)1932 268436
M:Communications
Mary-Jane Elliott / Emma Thompson
Tel +44 (0)20 7920 2342
E-mail: shield@mcomgroup.com
About Shield Therapeutics
Shield Therapeutics, founded in 2008, is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need. During 2011 Shield will be commencing a global pivotal Phase III study of its lead asset, ST10-021, for the treatment of iron deficiency anaemia associated with inflammatory bowel disease. The Company is headquartered in Wollerau, Switzerland. For further information, please visit www.shieldtherapeutics.com.